Comparison of investigator-reported and mortality adjudication committee-adjudicated fatal events (myocardial infarction, sudden death, sudden cardiac.

Slides:

Advertisements

Similar presentations

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Advertisements

Age-standardized mortality from ischaemic heart disease in European regions (men; age group years; year 2000) J Muller-Nordhorn, et al. Eur Heart.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Discontinuation of medication after nonfatal event: MI

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Patient populations by study group figure 10

Figure 1 Incidence and total numbers of SCD in patients with depressed LV systolic function and in patients with preserved LV function. The incidence of.

Baseline characteristics of patients

Age-related cumulative incidence for (A) serious adverse events (including death, heart failure admission, ventricular arrhythmia and cardiac transplant)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Long-term Data: INPULSIS®-ON

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

Survival without tracheostomy

MACE rate among CAD severity groups (total 0

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Bland–Altman comparison of lung clearance index (LCI) from multiple breath wash-out following open and modified closed circuit wash-in for both healthy.

Figure 2 Absolute difference in seasonal peak

Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Figure 4 Observational studies on multiple treatment strategies

A) Evolution of the yearly mortality rate from year 1 to year 15 of simulation according to the operating rule and to the scenario of organ scarcity. b)

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Composite of complications including cardiovascular (CV): acute myocardial infarction, cardiac arrhythmia requiring medical treatment and heart failure;

A white elephant or the elephant in the room

Swimmer plots showing post-nivolumab progression-free survival for the three main drugs studied according to the line of treatment in which they were received.

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Excluded and adjudicated male and female referrals—living and deceased participants were referred to the Sudden Unexpected Death in North Carolina (SUDDEN)

Improving Flexibility and Quality of Life for Your Patients: A Must?

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease Tetsuro Tsujimoto, Hiroshi Kajio

a) Mortality per time point (p<0

A family-based pulmonary rehabilitation (PR) programme enhanced the coping resources of the families of chronic obstructive pulmonary disease patients.

Kaplan-Meier analysis for the MACE-free or VA-free survival in patients with definite CS (A and C) or suspected CS (B and D) stratified by localisation.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Cumulative survival without events during 1 year of follow-up in patients treated with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril.

Cumulative survival without events during the first 42 days of treatment with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril (n=351)

CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

Weekly pneumococcal community-acquired pneumonia incidence rates over 5 years, with delineated school holiday periods by year. a) Year 1 (September 2008–2009).

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Differences in a) functional residual capacity (FRC) and b) lung clearance index (LCI) when using all trials in comparison with only the first two trials.

Kaplan-Meier survival estimates for major cardiovascular events.

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Physician perspectives on self-administration of i. v. α1-antitrypsin

Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Post-operative a) neutrophil counts, but not b) lymphocyte or c) platelet counts, were higher in current smokers than ex-smokers. #: time-points were statistically.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Bland–Altman comparison of functional residual capacity (FRC) measured from multiple breath wash-out following open and modified closed circuit wash-in.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to the presence of acute respiratory failure (ARF) and.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Comparison of cancer-specific survival in patients with nonsmall cell lung cancer detected incidentally by computed tomography (CT) (n=41) or chest radiography.

Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to a) Pneumonia Severity Index (PSI) risk classes and b)

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Percentage of positive results by pathogen among study patients with identified pathogens. “Other” includes respiratory viruses, Stenotrophomonas, Prevotella,

Performance of the Manchester Acute Coronary Syndromes decision rule in the derivation study. Performance of the Manchester Acute Coronary Syndromes decision.

Presentation transcript:

Comparison of investigator-reported and mortality adjudication committee-adjudicated fatal events (myocardial infarction, sudden death, sudden cardiac death and death) in the tiotropium Respimat 5 µg and HandiHaler 18 µg treatment groups. Comparison of investigator-reported and mortality adjudication committee-adjudicated fatal events (myocardial infarction, sudden death, sudden cardiac death and death) in the tiotropium Respimat 5 µg and HandiHaler 18 µg treatment groups. IR: incidence rate per 100 patient-years; MACE: major cardiovascular event; SOC: system organ class; PV: pharmacovigilance term; PT: preferred term; #: standardised MedDRA query (SMQ) ischaemic heart disease, sub-SMQ myocardial infarction. Robert A. Wise et al. ERJ Open Res 2017;3:00073-2016 ©2017 by European Respiratory Society